Objective To investigate the role of curcumin in the treatment of lupus nephritis (LN) by inhibiting the migration of neutrophils and the underlying mechanism involved. Methods Two lupus mouse models, ...
Background SLE is an independent risk factor for cardiovascular disease (CVD). This study aimed to determine which among QRISK2, QRISK3, Framingham Risk Score (FRS), modified Framingham Risk Score ...
Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, ...
Objective Long-term glucocorticoid use in SLE may have significant side effects; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the ...
Background and aims End-stage renal disease (ESRD) is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We studied the risk factors for development of ESRD among Filipino ...
Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021 (12 September, 2024) ...
1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab (16 May, 2024) ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Objectives To measure the expression level of the vacuolar protein sorting 13 (VPS13) gene and stimulator of interferon genes (STING) in patients with SLE with and without reported neuropsychiatric ...
Objectives To evaluate the time course of clinical response following anifrolumab treatment in patients with SLE. Methods A post hoc analysis was conducted using pooled data from phase III, randomised ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback